Sonoma Pharmaceuticals, Inc.

SNOA Healthcare Drug Manufacturers Specialty & Generic

Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.

1.13 0.02 −1.74%
Market cap
$5.5M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
3/9
Altman Z
−18.52
Beneish M
−1.69
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
16.27 12.10 12.15 12.50
Total non-current assets
1.84 1.86 1.48 1.36
Total Assets
18.11 13.96 13.62 13.86
Total current liabilities
5.45 4.83 4.22 4.32
Total non-current liabilities
6.07 6.03 5.97 5.75
Total liabilities
11.51 10.87 10.19 10.07
Common Equity (Total)
6.59 3.10 3.43 3.79
Shareholders Equity (Total)
6.59 3.10 3.43 3.79

Show all line items

In millions of $ except per-share values · columns are period end dates